Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IMVT | US
0.99
3.35%
Healthcare
Biotechnology
30/06/2024
04/10/2024
30.51
29.73
30.66
29.53
Immunovant Inc. a clinical-stage biopharmaceutical company develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York New York. Immunovant Inc. is a subsidiary of Roivant Sciences Ltd.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
35.0%1 month
54.5%3 months
46.6%6 months
45.1%-
-
7.53
0.00
0.00
-14.12
-
-
-298.26M
4.51B
4.51B
-
-
-
-
-64.55
12.62
19.47
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.05
Range1M
6.86
Range3M
8.69
Rel. volume
0.68
Price X volume
23.27M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 53.79 | 4.96B | -3.17% | n/a | 214.27% |
Alkermes plc | ALKS | Biotechnology | 28.97 | 4.77B | -0.10% | 12.07 | 28.66% |
Corcept Therapeutics Incorporated | CORT | Biotechnology | 45.43 | 4.75B | -0.94% | 38.88 | 0.95% |
BridgeBio Pharma Inc | BBIO | Biotechnology | 25.23 | 4.74B | 0.60% | n/a | -158.23% |
ADMA Biologics Inc | ADMA | Biotechnology | 20.29 | 4.73B | 4.05% | 138.46 | 75.10% |
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 47.63 | 4.50B | -0.75% | n/a | 7.75% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Arcellx Inc. Common Stock | ACLX | Biotechnology | 78.23 | 4.21B | 2.62% | n/a | 15.25% |
Axsome Therapeutics Inc | AXSM | Biotechnology | 86.59 | 4.16B | -7.13% | n/a | 186.48% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -14.12 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 7.53 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 46.58 | 74.67 | Lower Risk |
Debt to Equity | 0.00 | -1.82 | Expensive |
Debt to Assets | 0.00 | 0.26 | Cheaper |
Market Cap | 4.51B | 3.73B | Market Leader |